May/June 2026
May/June 2026 | Medical Retina
Drug Interactions in Immunosuppressive Therapy for Uveitis
A review of the toxic relationships to avoid when managing patients with uveitis.
Ioannis Papasavvas, MD, and Carl P. Herbort, Jr, MD, PD
May/June 2026 | Features
Novel MOAs in Wet AMD
The pipeline is full of therapies that hold promise for extending treatment efficacy.
Lejla Vajzovic, MD, FASRS; Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi
Popular Articles
April 2026 Insert
One to Watch: Samir N. Patel, MD
Samir N. Patel, MD
November/December 2025 | Meeting Minutes
Clambakes and Clinical Pearls at Nantucket Retina
This meeting is gearing up to celebrate 40 years of education.
Donald J. D’Amico, MD
March 2026 Supplement | Digital Supplement
From Vascular Curiosity to Neurodegenerative Disease: A Consensus Statement for the Diagnosis and Management of Macular Telangiectasia Type 2
Lejla Vajzovic, MD, FASRS; Sophie Bakri, MD; W. Lloyd Clark, MD; Diana Do, MD; Dean Eliott, MD; Roger Goldberg, MD; and Dante Pieramici, MD
April 2026 | Features
The Value of OCTA in Retinal Vascular Disease
Measuring retinal blood flow is easier than ever before, with new tools under investigation to further improve our ability to assess changes in the retinal vasculature.
Sarah Aman, MD; Viet-Hoan Le, PhD; Ruikang K. Wang, PhD; and Amir H. Kashani, MD, PhD
May/June 2026 | Features
Landmark Trials in AMD
A summary of the clinical trials that have shaped—and continue to shape—how we treat AMD.
Saghar Bagheri, MD, PHD; Alberto Quarta, MD; Rouzbeh Abbasgholizadeh, MD; Alessandro Feo, MD; Paolo Forte, MD; David Sarraf, MD; Michael S. Ip, MD; and SriniVas R. Sadda, MD, FARVO
Retina News
